文献速递类风湿关节炎

类风湿关节炎启动生物或靶向合成DMARDs后严重感染风险预测模型的开发与验证:全国队列研究

Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于法国国家健康数据系统2010-2023年全国队列,纳入启动b/tsDMARDs的成人RA患者,开发并内部验证严重感染(需住院)预测模型RAISE。模型含利妥昔单抗、英夫利西单抗、泼尼松≥7.5 mg/日、既往感染、肺病和糖尿病等预测因子,区分度中等(C指数0.71),校准良好,可提供6-24个月个体化风险估计。

要点

  • RAISE模型可基于常规数据预测RA患者启动b/tsDMARDs后6-24个月严重感染风险。
  • 利妥昔单抗(aHR 2.20)和英夫利西单抗(aHR 1.75)与严重感染风险升高相关。
  • 泼尼松≥7.5 mg/日、既往感染、肺病和糖尿病也是严重感染预测因子。

核心结论

  • RAISE模型能利用常规可得数据提供6、12、18和24个月个体化感染风险估计,优于既往预测工具的范围和相关性。
  • 该模型有助于基于风险的治疗规划和预防策略,但需外部验证后方可潜在国际采用。

研究设计与样本

  • 全国队列研究(2010-2023年),使用法国国家健康数据系统,纳入启动b/tsDMARDs的成人RA患者。
  • 数据集随机分为推导队列(66%)和验证队列(34%)进行内部(留出)验证,未进行外部验证。
  • 采用LASSO变量选择,继以多变量Cox模型估计校正风险比;推导队列用500次bootstrap重采样评估乐观校正性能。

主要发现

  • 中位随访12.5个月(IQR 5.3-33.3),推导队列和验证队列分别发生4,657和2,359例严重感染。
  • 预测因子包括利妥昔单抗(aHR 2.20,95%CI 1.98-2.44)、英夫利西单抗(aHR 1.75,95%CI 1.56-1.97)、泼尼松≥7.5 mg/日(aHR 1.45,95%CI 1.33-1.58)、既往感染(aHR 1.62,95%CI 1.48-1.77)、肺病(aHR 1.51,95%CI 1.40-1.64)和糖尿病(aHR 1.34,95%CI 1.23-1.46)。
  • 模型区分度中等(C指数0.71),校准良好(平均绝对误差≤0.07),评估时间范围为6-24个月。

关键数值与推荐

  • 严重感染定义为需住院的感染。
  • 模型预测6、12、18和24个月严重感染风险,区分度C指数0.71,校准平均绝对误差≤0.07。

临床怎么用

  • 可利用常规数据评估RA患者启动b/tsDMARDs后6-24个月严重感染风险,辅助治疗决策和预防策略制定。
  • 对接受利妥昔单抗、英夫利西单抗、泼尼松≥7.5 mg/日或有既往感染、肺病、糖尿病的患者应加强感染风险监测。

局限性

  • 本研究未进行外部验证。
  • 模型区分度仅为中等(C指数0.71)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop and validate a model to predict serious infection risk in rheumatoid arthritis (RA) patients initiating biologic or targeted synthetic DMARDs (b/tsDMARDs), and to implement it as an interactive tool (RAISE). METHODS: We conducted a nationwide cohort study (2010-2023) using the French National Health Data System. Adults with RA initiating a b/tsDMARD were included. The primary outcome was a serious infection (i.e. requiring hospitalization). The dataset was randomly split into a derivation cohort (66%) and a validation cohort (34%) for internal (hold-out) validation. Candidate predictors included demographics, treatment initiated, corticosteroid dose, prior infections and comorbidities. Variable selection used LASSO, followed by a multivariable Cox model to estimate adjusted hazard ratios. In the derivation cohort, 500 bootstrap resamples were used to assess optimism-corrected performance. Model discrimination and calibration (6-24 months) were evaluated in both cohorts. No external validation was performed at this stage. RESULTS: Over median follow-up of 12.5 months (IQR 5.3-33.3), 4,657 and 2,359 serious infections occurred in derivation and validation cohorts, respectively. Predictors included rituximab (aHR 2.20, 95% CI 1.98-2.44), infliximab (aHR 1.75, 1.56-1.97), corticosteroids ≥7.5 mg/day (aHR 1.45, 1.33-1.58), prior infection (aHR 1.62, 1.48-1.77), pulmonary disease (aHR 1.51, 1.40-1.64) and diabetes (aHR 1.34, 1.23-1.46). The model showed moderate discrimination (C-index 0.71) and calibration (mean absolute error ≤0.07). CONCLUSIONS: RAISE delivers personalized 6-, 12-, 18- and 24-month infection risk estimates using routinely available data, improving on the scope and relevance of earlier prediction tools. It enables risk-based treatment planning and preventive strategies, with potential for international adoption following external validation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Abboud M, Zureik M, Sbidian E, et al. Development and validation of a predictive model for the risk of serious infection in patients with rheumatoid arthritis initiating a biologic or targeted synthetic DMARD: a nationwide cohort study. Rheumatology (Oxford). 2026. PMID: 41335414. doi:10.1093/rheumatology/keaf644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。